Impaired functional performance despite hypertrophic enlargement, and an excessive accumulation of extracellular matrix, are hallmarks of the decompensated failing heart. Age is the leading risk factor for heart failure, and there is evidence suggesting that a number of age-associated changes in the cardiac phenotype predispose the heart to failure. The spontaneously hypertensive rat (SHR) exhibits compensated cardiac hypertrophy followed by a transition to heart failure in the last quartile of the lifespan, and thus provides a useful model of the transition from stable compensated hypertrophy to decompensated heart failure in the context of aging. The transition to failure in the SHR is accompanied by marked changes in the expression of an array of genes in the heart, including increased expression of a number of genes associated with the extracellular matrix. Drug treatments that prevent or reverse matrix gene expression in the SHR heart improve myocardial function and survival. The aged SHR model of decompensated heart failure has provided insight into the role of the extracellular matrix in the transition to failure, and can be useful to further investigate the mechanistic bases of heart failure, as well as to evaluate the potential efficacy of novel therapeutic approaches to the treatment of heart failure.
Introduction
encoding extracellular matrix proteins that make up the scaffolding that provides the framework in which Impaired functional performance despite hypertrophic myocytes function. enlargement characterizes the decompensated failing heart. Heart failure is relatively rare in younger individuals, Manifestations of decompensated function include venbut the incidence increases exponentially with advancing tricular dilatation, reduced fractional shortening, diminage [12] . Thus, age-associated changes in the myocardium ished ejection fraction, and decreased myocardial force likely contribute to the progression from stable hyperproduction. Interstitial fibrosis is a hallmark of cardiac trophy to dysfunction and heart failure. The spontaneously hypertrophy in heart failure [1] [2] [3] and other pathological hypertensive rat (SHR) exhibits compensated cardiac conditions [4, 5] , as well as normal aging [6] [7] [8] , but is hypertrophy for more than 50% of its lifespan, ultimately absent from hearts in which the stimulus for hypertrophy is becoming susceptible to cardiac dysfunction and congesexercise training [9] or hyperthyroidism [10] . Fibrosis tive heart failure at a mean age of 21 months [13, 14] . Thus increases the stiffness of the myocardium leading to it provides a useful model of the transition from stable diastolic dysfunction and exacerbation of heart failure [11] . compensated hypertrophy to decompensated heart failure Fibrosis results, in part, from increased expression of genes in the context of aging. This review will focus on the expression of extracellular matrix genes in the aged SHR model of decompensated heart failure.
The spontaneously hypertensive rat (SHR) model
ered as an unlikely, but possible, direct cause of the of heart failure transition to failure.
Systolic blood pressure becomes markedly elevated in early adulthood in the SHR, and remains elevated for the 3. Matrix gene expression during the transition to remainder of the lifespan (Fig. 1) . Most of the SHR failure in the aged SHR adulthood is associated with compensated left ventricular hypertrophy, progressive increases in LV volume, and
The transition to failure in the SHR is accompanied by fibrosis [13, 15] . At approximately 18 months of age, SHR marked changes in the expression of an array of genes in begin to develop signs of heart failure, and by 24 months the heart (Fig. 2) . Among the most prominent changes are of age, more than 50% have evidence of heart failure [14] .
increases in the levels of mRNAs encoding fibronectin, Salient features of heart failure in the SHR include cardiac collagen Type I, collagen Type III, and osteopontin; all hypertrophy, depressed myocardial function, extensive components of the extracellular matrix [18, 19] . In situ interstitial fibrosis, and apoptotic myocyte loss [14, 16, 17] .
hybridization suggested interstitial as well as perivascular The virtues of the SHR model of heart failure include its localization of collagen mRNA in failing hearts [20] . Since numerous similarities to human heart failure, with a increases in fibrillar collagen in the interstitium contribute spontaneous transition to failure in the context of aging, to tissue stiffness, increases in fibronectin and collagen and a relatively short lifespan compared to other mammals gene expression likely contribute to impaired function. The that allows for study in a timely manner. Another strength strong relationship between fibrosis and stiffness is best of the SHR model is that the primary stimulus for demonstrated by studies in which the angiotensin converthypertrophy and failure is hypertension, second only to ing enzyme (ACE) inhibitor lisinopril was used to treat myocardial infarction as a common precursor of heart young adult SHR with doses that allowed dissociation of failure in humans. Finally, the SHR model of failure has hypertrophy and fibrosis [21] . The experiments demonbeen studied extensively and a large literature has accumustrated that fibrosis was associated with LV stiffness lated describing its important features. One major limitaindependent of LV hypertrophy. Moreover, it was shown tion of the SHR model is that the genetic factors that cause that lisinopril could regress fibrosis and normalize LV hypertension remain unidentified, and thus must be considstiffness in aged SHR, thereby preventing LV dysfunction Fig. 1 . Age-associated changes in systolic blood pressure, left ventricular weight and left ventricular fibrosis in Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). SHR develop heart failure between 18 and 24 months of age (shaded area). Data replotted from A) reference [15] , B and C) reference [13] . Fig. 2 . Difference in mean levels of mRNA in the left ventricles of SHR with heart failure and age-matched SHR with hypertrophy but without failure. *, differences that are statistically significant (P,0.05). Data are from references [18, 19, 29] . [22] . Although it is difficult to separate cause and effect in necrotic cell death and apoptotic cell death [25, 26] . the failing heart without manipulating individual cardiac Necrosis is defined as cell death originating from an matrix components, a degenerative feedback interaction external insult that results in damage to the cell membrane between function and stiffness appears implicated. Identifiand release of cellular contents that in turn triggers a cation of upstream instigators of extracellular matrix classic inflammatory response, including the recruitment of proliferation could provide targets for therapies aimed at immune cells. Apoptosis, on the other hand, is typically preventing the deterioration of function associated with characterized by involution of the cell without triggering heart failure. There is considerable evidence from studies an inflammatory response. In the case of necrosis, interstiof extracardiac tissues that transforming growth factor b tial fibrosis would appear to be the expected response to 1 (TGFb ) plays a key role in regulating many aspect of the inflammatory signals. In the case of apoptosis, however, 1 remodeling process including the upregulation of ECM the fate of the space vacated by the apoptotic myocyte is genes. In the failing hearts of SHRs that exhibited markednot so clear. Although the myocyte is not believed to ly increased levels of fibronectin and collagen gene initiate an inflammatory response, it may still trigger expression, a small but significant increase in TGF-b events leading to interstitial fibrosis. Cardiac fibroblasts, 1 mRNA levels is also observed in both ventricles [18] . The which make the matrix components leading to interstitial upregulation of TGF-b gene expression observed in the fibrosis, are normally regulated tightly by their surround- 1 failing heart suggests that it may direct accumulation of ings (i.e. myocytes and matrix). When space is available, extracellular matrix, as it does in wound repair [23] .
however, as is the case in cell culture, fibroblasts rapidly Selective inhibition of the TGFb family of cytokines using initiate mitosis and proliferate while producing matrix a soluble type II receptor reduced fibrosis and collagen components until confluent. Whether or not cardiac fiformation in the adventitial layer of balloon-injured rat broblasts are similarly ''released'' from mitotic inhibition carotid arteries [24] . Another feature that resembles wound after myocyte apoptosis in vivo is not known. The findings repair is the preferential expression of alternatively spliced that both necrotic and apoptotic cell death are markedly fibronectin transcripts containing EIIIA and EIIIB segmore prevalent in the failing heart [17, 25] suggests that ments [18] . Why and how a process resembling wound myocyte loss [16] whether it be by necrosis, apoptosis, or repair is initiated in the failing heart is not well understood, both processes, stimulates salient features of the wound but there are several lines of evidence suggesting that repair process that result in interstitial fibrosis. It should be myocyte loss is one trigger stimulating interstitial fibrosis.
noted that current techniques used to identify necrosis and Myocytes may be lost by two well-described mechanisms, apoptosis have limitations [27] , and in the failing heart the two methods of cellular death may represent ends of a captopril treatment was initiated at 18 or 21 months of age. continuum rather than a true dichotomy. It will be an Thus, ACEI initiated prior to the onset of heart failure imposing challenge to determine the precise sequence of prevented changes in the expression of genes encoding events and signals that trigger the accumulation of interstimatrix and other proteins that that typically occur with tial fibrosis in the failing heart. advancing age in the SHR. It should be noted that the dose of captopril used in these studies significantly reduced systolic blood pressure, making it impossible to separate 4. Prevention or reversal of changes in matrix gene direct and indirect effects of ACEI on the fibrotic process expression by drug treatment of heart failure in the in the heart. Treatment of rats with captopril for 2-4 aged SHR months after they are identified with failure (SHR-F) improves survival, but does not significantly improve One of the few treatments available with established papillary muscle function, nor does it significantly reverse clinical efficacy for heart failure patients is inhibition of myocardial fibrosis [28] . Reactive treatment with captopril the angiotensin converting enzyme (ACEI) with pharmacodoes reverse some of the failure-associated changes in logical agents such as captopril. ACEI intercepts multiple gene expression as it leads to a marked increase in a-MHC effects of angiotensin II, including peripheral effects on mRNA and a significant reduction in the levels of TGFb 1 blood vessels that reduce blood pressure, and direct effects mRNA compared to untreated SHR-F (Fig. 4) . Inhibition on both myocytes and fibroblasts in the heart. To better of ACE with lisinopril does regress myocardial fibrosis in understand the mechanisms by which ACEI exerts it SHR of advanced age [22] , if treatment is begun prior to effects in vivo, captopril was administered to SHR at 12, the onset of signs of heart failure. In summary, preventive 18, and 21 months of age (prior to failure) and to SHR-F treatment of the SHR with ACEI is extremely successful, (after the onset of failure). Treatment of SHR rats with while the effects of reactive ACEI are ameliorative, but captopril from the age of 12 months completely prevented limited. Thus, there is a need to identify new therapeutic the development of heart failure [28] and markedly altered agents that can reverse established fibrosis and improve the pattern of gene expression (Fig. 3) . Captopril-treated myocardial function after the onset of failure [30] . rats had higher levels of a-MHC mRNA, and lower levels Identification of fibrosis as a contributor to the impaired of mRNA encoding ANF, collagen Type III, and TGFb function of the failing myocardium has led to attempts to 1 than age-matched SHR-F [29] . Similar results, although reverse fibrosis by agents that retard collagen formation or not quite as dramatic in every case, were obtained when disrupt collagen crosslinking. While colchicine is ineffec- Fig. 3 . Effect of captopril therapy initiated prior to the onset of failure on gene expression in the SHR left ventricle. There are no significant differences in the ages of the groups of rats. Data are from reference [28] . *, P,0.05 vs. WKY; †, P,0.05 vs. SHR-F; Rx, treatment with the angiotensin-converting enzyme inhibitor (ACEI) captopril beginning at 12 months of age.
The role of aging in the development of heart failure in the SHR
Age is the leading risk factor for heart failure in human patients. The incidence of heart failure increases more than 5-fold during the 7th and 8th decades of life [12] . From 1980 to 1991 the incidence of heart failure among the oldest Americans more than doubled [39] such that for Americans over the age of 65, heart failure is currently the single most common hospital discharge diagnosis and the most expensive medicare item. Aging in healthy humans and experimental animals is associated with a constellation of changes in the myocardium that reduce the reserve capacity of the heart to respond to a challenge [40, 7] . The best pharmaceutical therapies for heart failure remain ameliorative rather than reparative [41] . The heterogeneity and paucity of human heart tissue render it inadequate as a facts provide a rationale for animal models of heart failure and collagen Type III are not. Data are from reference [29] .
that feature aging to study the mechanisms that contribute to heart failure in the aging human population. tive in preventing fibrosis in SHR [31] , the lathyrogen
The transition from compensated hypertrophy to failure (b-amino proprionitrile (BAPN) prevents the increase in in the SHR seems to demonstrate quite well the consecollagen content and resting tension that occur after aortic quences of an interaction between ''normal aging'' and constriction of rats [32] . Furthermore, BAPN treatment disease. Although elevated blood pressure and marked decreases diastolic stiffness in pig myocardium [33] , and cardiac hypertrophy are established during the first quartile improves the function of left ventricular papillary muscles of the lifespan, myocardial function remains well compenfrom SHR with heart failure (unpublished observations).
sated through the second and third quartiles. During the While the experimental use of BAPN supports the notion last quartile of the SHR lifespan, heart failure is a common that reversal of fibrosis holds promise as a treatment for occurrence. While the accumulated effects of long term established heart failure, the adverse systemic effects of hypertension and the genetic nature of the model may play BAPN make it a poor candidate as a therapeutic approach contributory roles, it seems appropriate to hypothesize that to the treatment of heart failure. Therefore, the potential of the effects of ''normal aging'' reduce the adaptive capacity spironolactone, a competitive mineralocorticoid receptor of the SHR heart leading to heart failure. What changes (MR) antagonist offers a more realistic alternative to the occur in the hearts of normotensive rats with advancing treatment of the extracellular matrix component of heart age that might contribute to fibrosis and reduce the failure. Recent clinical trials have demonstrated efficacy of functional reserve capacity? spironolactone therapy in human patients with heart failure Interstitial fibrosis is a hallmark of cardiac hypertrophy [34] , but an understanding of the mechanisms by which in heart failure [1] [2] [3] and other pathological conditions spironolactone exerts its effects requires animal model [4, 5] , as well as normal aging [42, [6] [7] [8] , but is absent from studies. Spironolactone inhibits the production of collagen hearts in which the stimulus for hypertrophy is exercise by cultured cardiac fibroblasts [35] , suggesting that this training [9] or hyperthyroidism [10] . Fibrosis increases the may be a basis for its positive effects on survival of human stiffness of the myocardium leading to diastolic dysfuncheart failure patients. The basic requirements for a local tion and exacerbation of heart failure [11] . aldosterone signaling system are present in the heart, and
Fibronectin is an integral protein of the extracellular the levels of aldosterone in the rat heart are 17-fold higher matrix that acts to bind together various components of the than in the plasma [36] . In animal models of hyperaldosheart. The levels of fibronectin mRNA decrease somewhat teronism and hypertension, spironolactone therapy is effecbetween development and adulthood [43] , and are markedtive in preventing myocardial fibrosis [37, 38] . The effects ly increased in the senescent LV and atria [7] . Increased of spironolactone on the elevated expression of genes expression of fibronectin in the senescent heart is likely encoding extracellular matrix proteins, and increased incipart of an overall increase in the proportion of extracellular dence of apoptosis that occur in aging SHR are not known matrix as evidenced by the increase in collagen content and await study. [44, 45] . The expression of collagen genes undergoes a dramatic decrease from development to adulthood, and to TREs. It might be postulated, therefore, that a reduction then increases only slightly in the senescent heart [6, 43] .
in the number of THRs or RXRs might contribute to the While the relatively high level of collagen mRNA in the downregulation of a-MHC with age. In fact, a significant hearts of young rats does not result in accumulation of reduction (approximately 50%) between 6 and 24 months collagen, the barely detectable increase in collagen mRNA has been observed in the levels of THRb and RXRg observed in senescence is associated with a two-fold proteins in hearts of senescent rats [62] . Levels of mRNA increase in hydroxyproline content compared to levels in encoding these receptor subtypes are similarly depressed in adult hearts [6] . These finding suggest that collagen in the hearts of older rats, suggesting that the age-associated aged heart degrades at a slower rate. The increased levels decreases in THRb and RXRg are regulated transcriptionof fibronectin in the aged heart may contribute to the ally. reduced turnover of collagen by protecting collagen fibers
There is an age-associated decrease in b-adrenergic from degradation. The net effect is an accumulation of receptor (b-AR) responsiveness in the heart that appears to extracellular matrix with advancing age that conspires with be the result of age-related changes in multiple aspects of hypertension in the SHR to cause and / or exacerbate the receptor-signal transduction coupling. Decreases in both decline in myocardial function leading to failure.
the mRNA and protein levels of Gs [63, 52] , as well as in Age-associated changes in expression of non-matrix the mRNA levels of the b -AR [51] have been observed in 1 genes undoubtedly limit functional reserve of the aged older rats. Whether these changes occur progressively over myocardium as well [7] . The content of the a-MHC the lifespan or precipitously during development is not isoform (often referred to as the V isoform), which has a clear since only two ages were studied. In the case of Gsa l high ATPase activity, decreases progressively with age the change appears to occur after 6 months of age in the [46] . This decrease appears to be a major factor that male rat [63] and apparently does not occur in the female underlies the decreased myosin ATPase activity [47, 48] . [64] . Since the b -AR promoter is sensitive to thyroid 1 The mRNA coding for a-MHC also declines with age hormone [65] , decreased levels of THRs and RXRs may [47,49-51], and the diminished expression of this gene also contribute to the age-associated decrease in b -AR 1 with aging accounts, in large part, for the reduction in the gene expression. a-MHC content with aging. Conversely, the mRNA coding The sarco / endoplasmic reticulum Ca ATPase for the bMHC isoform (also referred to as the V isoform), (SERCA) gene which is downregulated in several models 3 which has a lower ATPase activity than the V isoform, of cardiac hypertrophy also exhibits lower levels of mRNA 1 exhibits a several fold increase [47,49] with aging and this in the senescent heart. With advancing age, the decrease in is the mechanism for the increase in bMHC protein that SERCA mRNA levels in the rat ventricle occurs between 8 occurs with aging. Phenotypic changes that occur with and 24 months of age [66] . This time course and the aging of the heart are, to some extent, due to changes in presence of a thyroid responsive element in the 59 upgene expression. The age-associated changes in MHC stream region of the [67, 68] suggests that the THR / RXR isoform expression are likely regulated transcriptionally, hypothesis described above for regulation of myosin heavy since corresponding changes are observed in a-and bchain may also apply to the SERCA gene. MHC mRNA levels. In addition to the isoform switch In adult rat hearts, there is high-level expression of the there may be a reduction in the total MHC mRNA levels atrial natriuretic peptide (ANP) gene in both the left and with age [52] . MHC gene expression is regulated by right atria. Among extra-atrial tissues studied, the ventrithyroxine via binding of thyroid hormone receptors cles of the heart express the most abundant level of ANP (THRs) to thyroid response elements (TREs) in the 59 mRNA, approximately 1-2% of that in atria [69] [70] [71] . In flanking regions of the genes. Binding of THRs to the TRE the developing embryo, ventricular as well as atrial of a-MHC upregulates its expression, while binding to the myocytes synthesize ANP [72, 73] , and before birth their b-MHC TRE inhibits [53] [54] [55] [56] [57] . Although levels of circulatrespective levels are comparable [74, 75] . One week after ing thyroid hormone may be slightly depressed with birth, granules containing ANP are widely distributed advancing age [58] , the magnitude of the MHC shift throughout both atria, but few granules are detectable in suggests other mechanisms may play a more important role ventricular tissues [72, 73] . The expression of ANP in adult in the age-associated changes observed. THRs are memventricular tissues is reactivated when the heart encounters bers of a superfamily of receptors which include retinoic overload [76, 77] . Aging from adulthood through senesacid receptors (RARs), Vitamin D receptors, and retinoid X cence is accompanied by a striking increase in the expresreceptors (RXRs). Three RXR genes have been cloned sion of the ANP gene in the ventricles [78] [79] [80] . The (a,b, g) and it has been shown that RXRs form heteroconcentration of ANP in hearts of older rats is closely dimers with other members of the superfamily [53, 59, 60] .
related to the magnitude of the LV/ body weight ratio [80] . The RXRa isoform plays a critical role in heart developVentricular ANP expression is apparently upregulated in ment as demonstrated by the lethal effects of RXRa gene every model of cardiac hypertrophy in which it has been knockout [61] . In many cases, the RXR-THR heterodimers examined, suggesting that the elevated expression of ANP bind with much higher affinity than do THR homodimers in the senescent heart may be a secondary consequence of the age-associated myocyte hypertrophy. By virtue of their age range. While this modest hypertrophic growth is relatively large mass, the ventricles can contribute sigcompensatory, it may reduce the remaining ''hypertrophic nificantly to circulating plasma ANP and thereby have reserve''. Assuming an upper limit on myocyte size, this considerable impact on systemic fluid balance. Work in leaves less reserve to respond to the demands of hypertencultured neonatal cardiac myocytes suggests that ANP may sion or other cardiovascular stresses. Hypertrophic growth inhibit hypertrophic growth [81] . The implications of this signals may be incompatible with other influences on finding for adult and senescent hearts remain to be cardiac myocytes and lead to necrosis or apoptosis. On this evaluated.
basis, inhibitors of cardiac hypertrophy might represent an Thus, there are striking changes in the expression of untapped therapeutic treatment for heart failure. Recent non-matrix genes with advancing age that contribute to the advances in our understanding of signaling pathways that aging phenotype as well as to the functional changes regulate cardiac hypertrophy present opportunities for such discussed previously. The second pattern to emerge from an approach. Two signaling pathways, one targeting this analysis is the age-associated downregulation of at transcriptional events in the nucleus, and one targeting least three thyroid-sensitive genes, a-MHC, b -AR and translational events in the cytoplasm, may be inhibited by 1 SERCA. As pointed out above, several aspects of thyroid currently available immunosuppressant drugs, cyclosporin, hormone signaling may be altered with aging in the heart, and rapamycin (Fig. 5 ) [93] [94] [95] [96] [97] . including a reduction in the availability of THR / RXR heterodimers; these changes may thus contribute to the senescent phenotype.
6. Prospects for future studies. One of the leading theories of aging is the notion that oxidative stress resulting from increased exposure to free Because it is extremely well characterized, and because radicals causes damage to cells [82, 83] . Effects of oxygen it shares a large number of characteristics with human radical species may include peroxidation of lipid memheart failure including age-associated events, the SHR branes, enzymatic deactivation, and DNA damage. Aging model should provide an excellent opportunity to address a into adulthood is associated with a reduced ability to number of important issues. First, it offers an opportunity defend against reactive oxygen [84] . In young adult SHR to further understand the mechanisms that contribute to the with established hypertension, altered levels of antioxidant progression to failure. It is an ideal model to use for enzymes are observed compared to normotensive WKY genomic / proteomic studies that have the potential to rats, such that decreased levels of superoxide dismutase identify unknown genes or proteins involved in the proand increased levels of glutathione peroxidase and catalase gression to heart failure. Differential display of mRNA are evident [85, 86] . Additionally, levels of xanthine oxifrom SHR and WKY has led to the discovery of altered dase activity, which may generate free radicals, are eleexpression of endogenous retrovirus, and to the finding of vated in hearts of young adult SHR [86] . The interactive markedly augmented osteopontin expression in heart faileffects of age and hypertension on the cardiac tolerance to ure [19, 98] . It is also a good model in which to study reactive oxygen species and the levels of antioxidant possible contributing factors such as the role of minerenzymes have not been evaluated, but may be another alocorticoid receptors in heart failure. As discussed above, factor that predisposes aged SHR to heart failure. In spironolactone reduces the mortality of heart failure paculture, oxygen radicals may initiate apoptosis in cardiac tients by mechanisms that can only be speculated upon at myocytes while inducing proliferation and expression of present. To address this issue, specific changes in the TGFb by cardiac fibroblasts [87] . If these cell types cardiac renin-angiotensin-aldosterone system should be 1 respond similarly to oxygen radicals in vivo, and if the evaluated in the aged SHR. Second, the aged SHR is an antioxidant system of the heart is compromised by the excellent model in which to evaluate therapy of heart interactive effects of age and hypertension, the potential failure as exemplified by a number of published studies contribution of oxygen radical damage to heart failure [28, 29, 31] . Future studies with the SHR could evaluate could be considerable.
both preventive and reparative treatments with a wide Cardiac hypertrophy is well-recognized to accompany range of therapeutic agents. This list should include agents aging in both rodents and humans [88, 89] . The senescent that may inhibit fibrosis, such as spironolactone, agents rat heart exhibits moderate LV hypertrophy (25%) comthat may inhibit myocardial hypertrophy such as cyclospared to hearts from young and middle-aged animals porin and rapamycin (Fig. 5) , specific angiotensin II [90, 91] . The majority of the increase in cardiac mass with receptor antagonists [99] , b-adrenergic receptor antagoaging is due to myocardial cell enlargement. In individual nists [100] , and agents that inhibit apoptosis [101] . Bemyocytes isolated from rats of 2, 6-9, and 24-26 months cause exercise training induces cardiac hypertrophy withof age, the average myocyte length increases by 20% out an increase in interstitial fibrosis [9] , it should be between 2 and 24-26 months of age, but the average slack studied in an animal model of heart failure to assess its sarcomere length does not change [92] . The average efficacy as a preventive measure against fibrosis and as a volume of individual cells approximately doubles over this supplement to pharmacological treatments aimed at revers- Fig. 5 . Signal transduction via the calcineurin and p70 S6 kinase pathways. Activation of each of these pathways has been linked to cardiac myocyte hypertrophy. Cardiac hypertrophy stimuli in the context of pathological stress may present the heart with incongruent signals that force the myocytes to ''choose'' between hypertrophy and apoptosis. Inhibition of either pathway represents a potential treatment of heart failure that might limit cardiac hypertrophy thereby reducing the incidence of apoptosis. CN, calcineurin; FRAP, FKBP-12-rapamycin associated protein; CAM, calmodulin; CsA, cyclosporin; NF /AT, nuclear factor of activated T-lymphocytes. See references [93] [94] [95] [96] . effects.
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